Kishore Gadde

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women
    K M Gadde
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Obes Res 9:544-51. 2001
  2. ncbi request reprint Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study
    Kishore M Gadde
    Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychiatry 68:1226-9. 2007
  3. ncbi request reprint Bupropion for weight reduction
    Kishore M Gadde
    Duke University Medical Centre, Box 3292, Durham, NC 27710, USA
    Expert Rev Neurother 7:17-24. 2007
  4. ncbi request reprint Escitalopram treatment of trichotillomania
    Kishore M Gadde
    Duke University Medical Centre, Durham, NC 27710, USA
    Int Clin Psychopharmacol 22:39-42. 2007
  5. ncbi request reprint Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks
    Kishore M Gadde
    Obesity Clinical Trials Program, Box 3292, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 114:974-84. 2006
  6. ncbi request reprint Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychopharmacol 26:409-13. 2006
  7. doi request reprint Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 377:1341-52. 2011
  8. ncbi request reprint Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC 27710, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:549-56. 2005
  9. ncbi request reprint Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial
    K M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC 27710, USA
    Int J Obes (Lond) 30:1138-42. 2006
  10. ncbi request reprint Zonisamide for weight loss in obese adults: a randomized controlled trial
    Kishore M Gadde
    Obesity Clinical Trials Program, Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 289:1820-5. 2003

Research Grants

  1. Zonisamide for Weight Reduction in Obese Adults
    Kishore Gadde; Fiscal Year: 2009

Detail Information

Publications23

  1. ncbi request reprint Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women
    K M Gadde
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Obes Res 9:544-51. 2001
    ..On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women...
  2. ncbi request reprint Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study
    Kishore M Gadde
    Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychiatry 68:1226-9. 2007
    ..Zonisamide and bupropion have been investigated for weight reduction in obese adults. We conducted a preliminary study comparing the effect on body weight of the combination of these 2 drugs versus zonisamide monotherapy...
  3. ncbi request reprint Bupropion for weight reduction
    Kishore M Gadde
    Duke University Medical Centre, Box 3292, Durham, NC 27710, USA
    Expert Rev Neurother 7:17-24. 2007
    ....
  4. ncbi request reprint Escitalopram treatment of trichotillomania
    Kishore M Gadde
    Duke University Medical Centre, Durham, NC 27710, USA
    Int Clin Psychopharmacol 22:39-42. 2007
    ..0001] and for completers [15.8 (1.0)-7.5 (1.2); F=10.1; P<0.0001]. Side effects were mild. Escitalopram treatment for 12 weeks led to significant improvement of trichotillomania in some patients in this small open-label trial...
  5. ncbi request reprint Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks
    Kishore M Gadde
    Obesity Clinical Trials Program, Box 3292, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 114:974-84. 2006
  6. ncbi request reprint Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychopharmacol 26:409-13. 2006
    ..To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine...
  7. doi request reprint Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 377:1341-52. 2011
    ....
  8. ncbi request reprint Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC 27710, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:549-56. 2005
    ..Recent studies with rimonabant, a cannabinoid type 1 receptor (CB(1)) antagonist, demonstrate clinically significant weight loss as well as reduction in metabolic syndromme burden in obese patients...
  9. ncbi request reprint Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial
    K M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, NC 27710, USA
    Int J Obes (Lond) 30:1138-42. 2006
    ..With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults...
  10. ncbi request reprint Zonisamide for weight loss in obese adults: a randomized controlled trial
    Kishore M Gadde
    Obesity Clinical Trials Program, Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 289:1820-5. 2003
    ..Weight loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials...
  11. ncbi request reprint The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients
    Kathryn M Connor
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychiatry 66:49-51. 2005
    ..To assess the effectiveness of aripiprazole, an atypical antipsychotic with dopamine- and serotonin-stabilizing properties, as monotherapy in treating obsessive-compulsive disorder (OCD)...
  12. pmc The effect of acute tryptophan depletion on emotional distraction and subsequent memory
    Lihong Wang
    Brain Imaging and Analysis Center, Duke University Medical Center, 2424 Erwin Road, Suite 501 Durham, NC 27705, USA
    Soc Cogn Affect Neurosci 4:357-68. 2009
    ..These findings highlight the importance of serotonin in negative memory with implications for mood disorders...
  13. ncbi request reprint Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia
    Jonathan R T Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 61:1005-13. 2004
    ..Generalized social phobia is common, persistent, and disabling and is often treated with selective serotonin reuptake inhibitor drugs or cognitive behavioral therapy...
  14. ncbi request reprint Serotonin-related gene polymorphisms and central nervous system serotonin function
    Redford B Williams
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3926, Durham, NC 27710, USA
    Neuropsychopharmacology 28:533-41. 2003
    ....
  15. ncbi request reprint Childhood socioeconomic status and serotonin transporter gene polymorphism enhance cardiovascular reactivity to mental stress
    Redford B Williams
    Department of Psychiatry and Behavioral Sciences, Box 3926, Duke University Medical Center, Durham, NC 27710, USA
    Psychosom Med 70:32-9. 2008
    ..We found the long allele associated with larger CVR to mental stress in a preliminary study of 54 normal volunteers...
  16. ncbi request reprint Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment
    Sandeep Vaishnavi
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychopharmacol 26:373-8. 2006
    ..92). Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0.01)...
  17. doi request reprint Combination therapy for obesity and metabolic disease
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, North Carolina 27710, USA
    Curr Opin Endocrinol Diabetes Obes 16:353-8. 2009
    ..There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases...
  18. ncbi request reprint Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial
    James W Anderson
    Department of Internal Medicine, Veterans Affairs Medical Center, University of Kentucky, Lexington, Kentucky, USA
    Obes Res 10:633-41. 2002
    ..To critically examine the efficacy of bupropion SR for weight loss...
  19. ncbi request reprint A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA
    Diabetes Care 30:1480-6. 2007
    ....
  20. ncbi request reprint Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
    Adesh K Jain
    Medical Research Institute, Slidell, Louisiana, USA
    Obes Res 10:1049-56. 2002
    ..This randomized, double-blind, placebo-controlled study evaluated the efficacy and tolerability of bupropion sustained-release (bupropion SR) in reducing weight and depressive symptoms in obese adults...
  21. ncbi request reprint Effect of rimonabant on weight and cardiometabolic risk factors
    Kishore M Gadde
    JAMA 296:649-50; author reply 650-1. 2006
  22. ncbi request reprint Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression
    Carla M Bann
    RTI International, Research Triangle Park, North Carolina 27709 2194, USA
    Depress Anxiety 20:114-22. 2004
    ..Future studies should explore whether patient beliefs have an even greater impact when patients are aware of the treatment they are receiving and can determine whether that treatment is consistent with their beliefs...
  23. ncbi request reprint Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial
    Benedetto Vitiello
    National Institute of Mental Health, Bethesda, MD 20892 9633, USA
    J Clin Psychopharmacol 25:243-9. 2005
    ..We assessed treatment adherence by measuring plasma hyperforin and evaluated the possible impact of adherence on study results...

Research Grants4

  1. Zonisamide for Weight Reduction in Obese Adults
    Kishore Gadde; Fiscal Year: 2009
    ..We will also systematically assess whether weight loss achieved with zonisamide treatment can reduce metabolic and cardiovascular risk factors. ..